Ecosio Gmbh
Total Consideration
$169.8M
Share price: $37.02
Purchase-Price Allocation
Goodwill
$119.7M
Intangibles
$6.0M
Contingent Earn-Out
$86.6M
Deferred Tax Liability
$12.1M
VERTEX, INC. — Key Metrics
2 years of history · ending 2025-12-31 · SEC EDGAR
Forensics
Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.
F-Score (Piotroski 0-9)
Turnover & Efficiency Analysis (days)
Expense Ratios
Working Capital Analysis
52-Week Range
Trailing Returns
ROIC vs WACC
Liquidity & Leverage Ratios
Earnings Quality (OCF/NI · FCF/NI · Sloan Accruals)
Return on Equity
3.3%
Return on Assets
0.6%
Return on Invested Capital
0.4%
Debt to Equity
1.30
Current Ratio
0.98
Quick Ratio
0.98
Asset Turnover
0.61
Days Sales Outstanding
89.46
Days Payables Outstanding
51.37
R&D / Revenue
11.2%
SBC / Revenue
7.7%
Capex / Revenue
10.8%
Working Capital
$-14M
Net Current Asset Value
$-451M
Invested Capital
$596M
OCF / Net Income
22.96
FCF / Net Income
22.96
Accruals Ratio (Sloan)
-12.5%
Net Debt
$23M
Net Debt / EBITDA
0.24
Interest Coverage
—
Cash Coverage
—
Dividend Coverage
—
Capex Coverage
2.30
Tangible Common Equity
$-134M
TCE / Total Assets
-10.5%
Goodwill / Total Assets
30.9%
NOPAT
$2M
Cash ROIC
29.8%
WC / Revenue
-1.9%
Capex / D&A
0.87
Reinvestment Rate
-4158.3%
Total Payout Ratio
140.0%
Asset Growth vs Revenue Growth
-3.3%
Revenue 5Y CAGR
14.8%
FCF 5Y CAGR
33.8%
EBITDA 5Y CAGR
—
Book Value 5Y CAGR
2.5%
Stock Price (FY-end)
$20
Operating Leverage
-0.70
Beta (5Y)
1.15
Cost of Equity
10.3%
Cost of Debt (after tax)
—
52W High
$59
52W Low
$19
Trailing Return 1Y
-62.1%
Trailing Return 5Y
-45.9%
F-Score (Piotroski)
7.00
Earnings Forecasts
Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).
Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.
EPS — Consensus vs Actual
Revenue — Consensus vs Actual
Stock Price on Earnings Dates
VERTEX, INC. — Effective Tax Rate ReconciliationNEW
Bridges from the federal statutory rate (21% post-TCJA) to the effective tax rate via the issuer's tax-note reconciliation lines. Sourced from EffectiveIncomeTaxRateReconciliation* flat CompanyFacts concepts. Conditional lines (R&D credits, FDII, SBC, valuation allowance, etc.) only render when the issuer discloses them. Persistent divergence between accrual tax expense and cash taxes paid is a leading signal for deferred-tax buildup.
Effective Rate Trend
| Reconciliation Line | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Federal Statutory Rate | 21.00% | 21.00% | 21.00% | 21.00% | 21.00% | 21.00% |
| State & Local Income Taxes | 1.70% | -17.30% | -4.40% | 1.40% | 5.15% | 23.50% |
| Foreign Rate Differential | 0.10% | -24.30% | -13.30% | -6.80% | 43.60% | — |
| Other Adjustments | -0.50% | 12.80% | -1.70% | 0.70% | 9.70% | — |
| R&D Tax Credits | — | — | — | -26.80% | 2.58% | 59.50% |
| SBC (Nondeductible) | 5.40% | 115.90% | -17.60% | 28.80% | -10.77% | — |
| Valuation Allowance Change | -0.10% | -9.50% | -4.20% | -15.60% | 35.17% | — |
| Tax Law Change | 23.50% | — | — | — | — | — |
| Effective Tax Rate | 30.40% | 62.30% | -21.50% | 39.60% | 28.62% | 4.90% |
Cash vs Accrual
| Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Income Tax Expense (Accrual) | −$32.8M | −$2.4M | $2.2M | −$8.6M | $54.6M | $368.0K |
| Income Taxes Paid (Cash) | $588.0K | $1.3M | $3.1M | $5.7M | $8.6M | $1.9M |
VERTEX, INC. — M&A AcquisitionsNEW
Per-deal acquisition disclosures sourced from us-gaap:BusinessAcquisitionAxis dimensional XBRL. Each card surfaces the deal's purchase-price allocation (goodwill vs intangibles vs liabilities), contingent consideration (unpaid earn-outs), and pro-forma combined-entity numbers. Probability-of-Success (PoS) factor on biotech targets is the ASC 805 contingent-consideration valuation — higher = closer to commercialization, higher implied target value.